Human Epilepsy: Understanding Biology To Improve Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$16,657,948.00
Summary
Our team of neurologists, molecular geneticists, physiologists and brain imaging specialists and leads the world in the discovery of the genetic causes of epilepsy. Through this work we will identify genes underlying epilepsy and study how genetic variations result in the development of seizures. Advanced brain imaging will be used to understand the effects of genetic variation on brain structure and function. This study may lead to new diagnostic methods and treatments for epilepsy.
ADVANCING THE EVIDENCE BASE FOR CARE AND POLICY IN PRIORITY HEALTH AREAS
Funder
National Health and Medical Research Council
Funding Amount
$11,195,727.00
Summary
This program will improve health care and policy through clinical trials research and better methods for combining trial evidence. The team will tackle priority health areas to reduce death and serious disability: in particular in cancer, cardiovascular disease, diabetes, obesity and neonatal diseases. The program team includes clinicians, epidemiologists, trialists, biostatisticians, and health economists and collaborative networks of clinical investigators in each disease area.
Improving Stroke Outcomes: Attenuating Progression And Recurrence
Funder
National Health and Medical Research Council
Funding Amount
$9,331,996.00
Summary
Stroke is the second most common cause of death and major cause disability. There are few proven interventions, so we need to introduce new ones. We developed a bench to bedside program to introduce new stroke therapies and its early secondary prevention. Our general goal is to provide evidence for their effectiveness and safety. We will use animal stroke models, markers in the blood to help diagnose and predict stroke outcome and imaging to help select patients for several clinical trials.
Musculoskeletal Pain And Disability: Improving Outcomes Through Conservative Interventions
Funder
National Health and Medical Research Council
Funding Amount
$8,549,204.00
Summary
Musculoskeletal conditions (particularly back pain and osteoarthritis) are highly prevalent and have a major impact on health and well being of Australians. This Program aims to resolve the major priorities in the field: optimal methods to target the right treatment to the right person at the right time through our unique strategy to understand mechanisms and identify patient subgroups, and establish optimal methods to overcome barriers to translation of research to policy and practice.
Improving The Health Of People With Problematic Drug Use: Hepatitis C And Drug Dependence
Funder
National Health and Medical Research Council
Funding Amount
$9,060,140.00
Summary
Problematic drug use is the major risk factor to health among Australians aged 15-49 years. The dual harms of drug dependence and hepatitis C virus (HCV) faced by people who use drugs compel improved drug dependence management and HCV prevention and treatment. This Program Grant will improve the lives of people with problematic drug use by investigating health impacts of drug use and evaluating new strategies for managing drug dependence and eliminating HCV among people who use drugs.
Tropical Disease - Immunity, Pathogenesis And Vaccine Development: Global Translation
Funder
National Health and Medical Research Council
Funding Amount
$17,988,456.00
Summary
Tropical diseases create a significant human and economic burden worldwide - particularly in resource-poor settings. Around half of the world's population is at risk of malaria. In Australia, Streptococcal and parasitic worm infections are particularly common in indigenous communities. This Program brings together leading experts to tackle these major health challenges. They are investigating how the body reacts to infection and creating new drugs and vaccines to eradicate these diseases.
Clinical, Public Health And Policy Interventions To Combat Cardiovascular Diseases
Funder
National Health and Medical Research Council
Funding Amount
$24,025,090.00
Summary
This program will generate and translate evidence from high-quality research designed to inform the decisions of health care providers and policy makers about best strategies for the prevention and treatment of cardiometabolic conditions. The program, with both domestic and global relevance, will address a spectrum of issues, with translational outcomes for clinical research.
Central to improving the management of patients with cancer is an understanding of the molecular drivers of cancer. Based on our fundamental discoveries about the role of cell growth and perturbed cell signalling as drivers of cancer we will use the integration of molecular and imaging biomarkers with targeted therapies to translate this knowledge into better outcomes for cancer patients with defined molecular drivers of their cancer.